Skip to main content

Table 3 Medication adherence for the UMEC/VI and TIO cohorts

From: Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

  UMEC/VI (N = 3929) TIO (N = 3929) p valuea Difference (95% CI) Odds ratio (95% CI)
PDC, mean (SD) [median] 0.44 (0.32) [0.33] 0.37 (0.31) [0.25]  < 0.001 0.06 (0.05, 0.08)
Proportion with PDC ≥ 0.8, n (%) 863 (22.0) 646 (16.4)  < 0.001 1.44 (1.28, 1.61)
  1. ap-values were calculated using paired t-tests for mean PDC and McNemar tests for proportion of patients with PDC ≥ 0.8
  2. CI, confidence interval; PDC, proportion of days covered; SD, standard deviation; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol